期刊
NEUROLOGIA MEDICO-CHIRURGICA
卷 57, 期 7, 页码 321-330出版社
JAPAN NEUROSURGICAL SOC
DOI: 10.2176/nmc.nmc.ra.2016-0334
关键词
brain tumor immunotherapy; glioblastoma; autologous formalin-fixed tumor vaccine; PD-1; immune checkpoint inhibitor
资金
- Tsukuba University Hospital
- Grants-in-Aid for Scientific Research [15K10327] Funding Source: KAKEN
To date, clinical trials of various vaccine therapies using autologous tumor antigens or tumor-associated/specific antigen peptide with adjuvants have been performed to treat patients with high-grade gliomas (HGG). Furthermore, immune checkpoint pathway-targeted therapies including anti-programmed cell death 1 (PD-1) antibody have been remarkably effective in other neoplasms, and various clinical trials with anti-PD-1 antibody in patients with HGG have started to date. It is possible that up-regulation of immune checkpoint molecules in tumor tissues after vaccine therapy may be one of the mechanisms of vaccine failure. Multiple preclinical studies indicate that combination therapy with vaccination and -immune checkpoint blockade is effective for the treatment of malignant tumors including HGG. Thus, -immunotherapy, especially combination therapy with vaccine and immune checkpoint inhibitors, may be a promising strategy for treatment of patients with HGG.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据